PK parameters (mean ± standard deviation) of imatinib mesylate in patients on day 1
Dose/day, mg/m2 . | No. of patients . | tmax, h . | Cmax, μg/mL . | T1/2, h . | AUC(0-24 h), μg.h/mL . | AUC(0-∞), μg.h/mL . | Vz/F, L . | CI/F, L/h . |
|---|---|---|---|---|---|---|---|---|
| 260 | 6 | 3.5 ± 2.5 | 3.6 ± 2.0 | 8.9 ± 1.2 | 51.0 ± 34.9 | 60.6 ± 4.0 | 119 ± 83 | 8.9 ± 5.8 |
| 340 | 8 | 3.7 ± 2.1 | 2.5 ± 0.9 | 9.2 ± 1.9 | 32.1 ± 13.0 | 39.6 ± 17.4 | 167 ± 84 | 12.8 ± 6.8 |
| 440 | 4 | 5.0 ± 2.0 | 5.4 ± 4.3 | 12.8 ± 2.5 | 76.1 ± 54.8 | 103.3 ± 64.8 | 190 ± 213 | 9.3 ± 9.4 |
| 570 | 4 | 2.9 ± 1.3 | 8.5 ± 9.2 | 14.8 ± 12.9 | 106.7 ± 113.6 | 150.7 ± 133.1 | 109 ± 88 | 5.6 ± 2.8 |
Dose/day, mg/m2 . | No. of patients . | tmax, h . | Cmax, μg/mL . | T1/2, h . | AUC(0-24 h), μg.h/mL . | AUC(0-∞), μg.h/mL . | Vz/F, L . | CI/F, L/h . |
|---|---|---|---|---|---|---|---|---|
| 260 | 6 | 3.5 ± 2.5 | 3.6 ± 2.0 | 8.9 ± 1.2 | 51.0 ± 34.9 | 60.6 ± 4.0 | 119 ± 83 | 8.9 ± 5.8 |
| 340 | 8 | 3.7 ± 2.1 | 2.5 ± 0.9 | 9.2 ± 1.9 | 32.1 ± 13.0 | 39.6 ± 17.4 | 167 ± 84 | 12.8 ± 6.8 |
| 440 | 4 | 5.0 ± 2.0 | 5.4 ± 4.3 | 12.8 ± 2.5 | 76.1 ± 54.8 | 103.3 ± 64.8 | 190 ± 213 | 9.3 ± 9.4 |
| 570 | 4 | 2.9 ± 1.3 | 8.5 ± 9.2 | 14.8 ± 12.9 | 106.7 ± 113.6 | 150.7 ± 133.1 | 109 ± 88 | 5.6 ± 2.8 |
PK indicates pharmacokinetics; mg/m2, milligram per square meter; No., number; tmax, h, time to reach Cmax (hours); Cmax, μg/mL, maximum mean plasma concentrations (microgram per milliliter); t1/2, h, half-life (hours); AUC(0-24h), μg.h/mL, area-under-the concentration-time curve, from time 0 to 24 hours (microgram times hour per milliliter); AUC(0-∞), μg.h/mL, area-under-the concentration-time curve, from time 0 to infinity (microgram times hour per milliliter); Vz/F, L, apparent volume of distribution during terminal phase after oral intake (liter); and CI/F, L/h, apparent total plasma clearance of drug after oral intake (liter per hour).